Production (Stage)
Rakovina Therapeutics Inc.
RKVTF
$0.0383
$0.00061.59%
OTC PK
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 135.55% | -2.28% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 43.47% | 25.70% | |||
| Operating Income | -43.47% | -25.70% | |||
| Income Before Tax | -42.35% | -24.18% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -42.35% | -24.18% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -42.35% | -24.18% | |||
| EBIT | -43.47% | -25.70% | |||
| EBITDA | -51.14% | -30.91% | |||
| EPS Basic | -27.71% | 2.35% | |||
| Normalized Basic EPS | -25.00% | 1.89% | |||
| EPS Diluted | -56.63% | 2.35% | |||
| Normalized Diluted EPS | -25.00% | 1.89% | |||
| Average Basic Shares Outstanding | 11.77% | 26.81% | |||
| Average Diluted Shares Outstanding | 11.77% | 26.81% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||